938062-38-5

Basic information

• Product Name: 1H-Indazole,6-broMo-3-Methoxy-
• Synonyms: 1H-Indazole,6-broMo-3-Methoxy-;6-BroMo-3-Methoxy-1H-indazole
• CAS NO: 938062-38-5
• Molecular Formula: C8H7BrN2O
• Molecular Weight: 227.05798
• Mol File: 938062-38-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1H-Indazole,6-broMo-3-Methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indazole,6-broMo-3-Methoxy-(938062-38-5)
• EPA Substance Registry System: 1H-Indazole,6-broMo-3-Methoxy-(938062-38-5)

Safety Data

• Hazardous Substances Data: 938062-38-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
1H-Indazole, 6-bromo-3-methoxyis used as a building block in the synthesis of new compounds. Its unique structure and functional groups allow for versatile chemical reactions, enabling the creation of a wide range of organic compounds with diverse properties and applications.
Used in Pharmaceutical Applications:
1H-Indazole, 6-bromo-3-methoxyis used as a research tool in drug discovery and development. The bromine and methoxy groups can influence the compound's biological activity, making it a promising candidate for the development of new pharmaceutical agents. Its potential applications in this field include the treatment of various diseases and conditions, as well as the enhancement of drug delivery systems.
Used in Medicinal Chemistry:
1H-Indazole, 6-bromo-3-methoxyis utilized in medicinal chemistry for its potential to modulate biological targets and pathways. The presence of the bromine and methoxy groups can affect the compound's binding affinity and selectivity, making it a valuable tool for the design and optimization of novel therapeutic agents.

Upstream product

• 885521-92-6 6-bromo-1H-indazol-3-ol 
• 179232-29-2 methyl 4-bromo-2-fluorobenzoate 
• 79762-54-2 6-bromo-1H-indazole 

Relevant articles and documents

6-bromo-3-methoxy-1-phenyl-1H-indazole as well as synthesis method and application thereof

The invention provides 6-bromo-3-methoxy-1-phenyl-1H-indazole as well as a synthesis method and application thereof, and the synthesis method comprises the following steps: taking 6-bromoindazole as a raw material, and reacting with nitrate in a first organic solvent; the obtained 6-bromo-3-nitro-1H-indazole and sodium methoxide are subjected to a reaction in a second organic solvent; and then the obtained 6-bromine-3-methoxy-1H-indazole reacts with phenyl halide in a third organic solvent in the presence of alkali, a ligand and copper iodide, and the 6-bromine-3-methoxy-1H-indazole is obtained. According to the invention, the 6-bromo-3-methoxy-1-phenyl-1H-indazole is synthesized by adopting three steps, so that tedious reaction operation and use of expensive, high-toxicity and high-risk reagents in the prior art are avoided, and the method is a simple, feasible, green and environment-friendly synthesis method. In addition, raw materials and auxiliary materials used in the synthesis method are cheap and easy to obtain, reaction conditions are mild, operation is easy and convenient, the process is stable, the whole synthesis process is high in controllability, aftertreatment is simple, and the method is suitable for large-scale production.

Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy

GPR120 agonists have therapeutic potential for the treatment of diabetes, but few selective agonists have been reported. We identified an indazole-6-phenylcyclopropylcarboxylic acid series of GPR120 agonists and conducted SAR studies to optimize GPR120 potency. Furthermore, we identified a (S,S)-cyclopropylcarboxylic acid structural motif which gave selectivity against GPR40. Good oral exposure was obtained with some compounds displaying unexpected high CNS penetration. Increased MDCK efflux was utilized to identify compounds such as 33 with lower CNS penetration, and activity in oral glucose tolerance studies was demonstrated. Differential activity was observed in GPR120 null and wild-type mice indicating that this effect operates through a mechanism involving GPR120 agonism.